Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 4/20 | 0.64 |
| ▸ | HTR2C | P28335 | 3/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.64 |
| ▸ | DRD3 | P35462 | 3/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | MLNR | O43193 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.64 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16575625 | 0.90 | CASR (0.69) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL9989657 | 0.90 | CASR (0.69) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL3226247 | 0.89 | HTR2C (0.64) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL8203596 | 0.89 | HTR2C (0.64) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL28127001 | 0.88 | CASR (0.63) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL28127003 | 0.88 | CASR (0.63) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL7912988 | 0.88 | HTR2C (0.63) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL10123767 | 0.87 | CASR (0.65) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL10108626 | 0.87 | CASR (0.62) | CASRHTR2CADRA2CSLC6A4DRD3 | |
| SCHEMBL20307877 | 0.86 | HTR2C (0.64) | CASRHTR2CADRA2CSLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318417-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-12-29 | — | — | US | disclosed |
| US-20110178326-A1 | UNSATURATED CINACALCET SALTS AND PROCESSES FOR PREPARING CINACALCET HYDROCHLORIDE | ACTAVIS GROUP PTC EHF (IS) | 2011-07-21 | — | — | US | disclosed |
| WO-2010067204-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010015935-A2 | UNSATURATED CINACALCET SALTS AND PROCESSES FOR PREPARING CINACALCET HYDROCHLORIDE | ACTAVIS GROUP PTC EHF (IS) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318417-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SLC6A12 | CASR 1297/4885HTR2C 1434/4885ADRA2C 280/4885 |
| US-20110178326-A1 | UNSATURATED CINACALCET SALTS AND PROCESSES FOR PREPARING CINACALCET HYDROCHLORIDE | OTC, HMGCR, SI | CASR 111/4885HTR2C 4338/4885ADRA2C 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.